Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases

Category Primary study
JournalCancer Management and Research
Year 2022
This article has no abstract
Epistemonikos ID: e02240a2dc74ec1ab7ebe19717f08949a363e861
First added on: Feb 15, 2025